scholarly journals A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

2017 ◽  
Vol 6 (8) ◽  
pp. 1904-1914 ◽  
Author(s):  
Benjamin Izar ◽  
William Sharfman ◽  
F. Stephen Hodi ◽  
Donald Lawrence ◽  
Keith T. Flaherty ◽  
...  
Keyword(s):  
Phase I ◽  
Metastatic Melanoma ◽  
Dose Escalation ◽  
Braf Mutation ◽  
Locally Advanced ◽  
Open Label ◽  
Dose Escalation Study ◽  
Mutation Status ◽  
Label Dose

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers

2021 ◽  
pp. clincanres.0845.2021
Author(s):  
Adi Diab ◽  
Omid Hamid ◽  
John A Thompson ◽  
Willeke Ros ◽  
Ferry A.L.M. Eskens ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Escalation ◽  
Locally Advanced ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose

Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3033-3033 ◽  
Author(s):  
A. L. Ho ◽  
J. C. Bendell ◽  
J. M. Cleary ◽  
G. K. Schwartz ◽  
H. A. Burris ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose
Sign in / Sign up

Export Citation Format

Share Document